BONEX.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 11:29):

Stats
Today's Volume	266 689
Average Volume	183 224
Market Cap	15.62B
EPS	SEK0 ( 2024-04-24 )
Next earnings date	( SEK0 ) 2024-07-11
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	63.36
ATR14	SEK0.335 (0.14%)

Volume Correlation

Long: 0.22 (neutral)

Short: 0.58 (weak)

Signal:(51.935) Neutral

Bonesupport Holding AB Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bonesupport Holding AB Correlation - Currency/Commodity

0.31
( neutral )

0.18
( neutral )

0.00
( neutral )

0.45
( neutral )

-0.24
( neutral )

0.44
( neutral )

Bonesupport Holding AB Financials

Annual	2023
Revenue:	SEK591.08M
Gross Profit:	SEK533.12M (90.20 %)
EPS:	SEK3.77

Q4	2023
Revenue:	SEK172.74M
Gross Profit:	SEK158.60M (91.81 %)
EPS:	SEK0.170

Q3	2023
Revenue:	SEK158.20M
Gross Profit:	SEK145.78M (92.15 %)
EPS:	SEK3.52

Q2	2023
Revenue:	SEK140.39M
Gross Profit:	SEK128.20M (91.32 %)
EPS:	SEK0.0800

Financial Reports:

No articles found.

Bonesupport Holding AB

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.